This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
G1SecL05
From Proteopedia
(→Table of Contents) |
(→Table of Contents) |
||
| Line 4: | Line 4: | ||
= Table of Contents= | = Table of Contents= | ||
| - | *''' | + | *'''1. Background ''' |
| - | *''' | + | *'''2. Development of the recombinant vaccine |
| - | *''' | + | *'''3. Introduction to the LA-2 fab complex |
| - | *''' | + | *'''4. Binding affinitity and interactions in the LA-2 fab complex''' |
| - | *''' | + | *'''5. Structural Defects in the vaccine''' |
| - | *''' | + | *'''6. Discussion''' |
'''Background''' | '''Background''' | ||
Revision as of 02:00, 29 April 2013
LA-2 FAB with OspA Complex
Table of Contents
- 1. Background
- 2. Development of the recombinant vaccine
- 3. Introduction to the LA-2 fab complex
- 4. Binding affinitity and interactions in the LA-2 fab complex
- 5. Structural Defects in the vaccine
- 6. Discussion
Background
Lyme disease, discovered in 1975, is a vector- borne disease caused by the inoculation of spirochete borrelia into the skin by members of hard bodied ticks of the family Ixodidae. Symptoms include arthritis at major joints, neurological problems such as reduced memory and poor ability to concentrate, and characteristic lesions erythema migans, more commonly known as the bull’s eye rash. A major outer surface membrane protein of Borrelia, ospA, plays a key role in immunity against Lyme disease through its binding to the antibody LA-2 fab.
Development of the recombinant vaccine
|
Proteopedia Page Contributors and Editors (what is this?)
Moazzam Khan, Supriya Kannan, Rubab Farhat, Noopoor Akruwala, Michal Harel
